<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04034354</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-17T00:06:11+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">How best to monitor the specific side effects of medical treatments of Cushing’s disease</title>
            <author role="aut">
              <persName>
                <forename type="first">Frederic</forename>
                <surname>Castinetti</surname>
              </persName>
              <email type="md5">16ff47754607d4b03c91f91d034f6b3d</email>
              <email type="domain">ap-hm.fr</email>
              <idno type="idhal" notation="string">frederic-castinetti</idno>
              <idno type="idhal" notation="numeric">16755</idno>
              <idno type="halauthorid" notation="string">13281-16755</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-1808-8800</idno>
              <idno type="IDREF">https://www.idref.fr/113296061</idno>
              <affiliation ref="#struct-527039"/>
              <affiliation ref="#struct-1006998"/>
              <affiliation ref="#struct-533507"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Valérie</forename>
                <surname>Gall</surname>
              </persName>
              <email type="md5">dfd44b1ba32f373cf0d3d1d472537a90</email>
              <email type="domain">univ-amu.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-04-04 11:05:32</date>
              <date type="whenModified">2024-05-07 13:39:44</date>
              <date type="whenReleased">2023-04-13 16:13:38</date>
              <date type="whenProduced">2022-12</date>
              <date type="whenEndEmbargoed">2023-06-01</date>
              <ref type="file" target="https://amu.hal.science/hal-04034354v1/document">
                <date notBefore="2023-06-01"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://amu.hal.science/hal-04034354v1/file/Final_Castinetti_Manuscript_2022_BestPractice%20IAD%20propre.pdf" id="file-4057517-3540634">
                <date notBefore="2023-06-01"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="493131">
                <persName>
                  <forename>Valérie</forename>
                  <surname>Gall</surname>
                </persName>
                <email type="md5">dfd44b1ba32f373cf0d3d1d472537a90</email>
                <email type="domain">univ-amu.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04034354</idno>
            <idno type="halUri">https://amu.hal.science/hal-04034354</idno>
            <idno type="halBibtex">castinetti:hal-04034354</idno>
            <idno type="halRefHtml">&lt;i&gt;Best Practice and Research: Clinical Endocrinology and Metabolism&lt;/i&gt;, 2022, 36 (6), pp.101718. &lt;a target="_blank" href="https://dx.doi.org/10.1016/j.beem.2022.101718"&gt;&amp;#x27E8;10.1016/j.beem.2022.101718&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Best Practice and Research: Clinical Endocrinology and Metabolism, 2022, 36 (6), pp.101718. &amp;#x27E8;10.1016/j.beem.2022.101718&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4057517-3540634"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="UNIV-AMU">Aix Marseille Université</idno>
            <idno type="stamp" n="MMG">Marseille Medical Genetics</idno>
            <idno type="stamp" n="MARMARA">Institut Marseille Maladies Rares</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">How best to monitor the specific side effects of medical treatments of Cushing’s disease</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Frederic</forename>
                    <surname>Castinetti</surname>
                  </persName>
                  <email type="md5">16ff47754607d4b03c91f91d034f6b3d</email>
                  <email type="domain">ap-hm.fr</email>
                  <idno type="idhal" notation="string">frederic-castinetti</idno>
                  <idno type="idhal" notation="numeric">16755</idno>
                  <idno type="halauthorid" notation="string">13281-16755</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-1808-8800</idno>
                  <idno type="IDREF">https://www.idref.fr/113296061</idno>
                  <affiliation ref="#struct-527039"/>
                  <affiliation ref="#struct-1006998"/>
                  <affiliation ref="#struct-533507"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">11046</idno>
                <idno type="issn">1521-690X</idno>
                <title level="j">Best Practice and Research: Clinical Endocrinology and Metabolism</title>
                <imprint>
                  <publisher>Elsevier</publisher>
                  <biblScope unit="volume">36</biblScope>
                  <biblScope unit="issue">6</biblScope>
                  <biblScope unit="pp">101718</biblScope>
                  <date type="datePub">2022-12</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/j.beem.2022.101718</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="sdv.mhep">Life Sciences [q-bio]/Human health and pathology</classCode>
              <classCode scheme="halDomain" n="sdv.mhep.em">Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>The first-line treatment of Cushing’s disease is transsphenoidal surgery. Medical treatment of Cushing’s disease can be considered in several situations: as a presurgical treatment in patients with severe comorbidities, when surgery fails, or while waiting for the maximal efficacy of radiation techniques. Several modalities of medical treatment are possible, from adrenal-targeting drugs (steroidogenesis inhibitors) to pituitary-targeting drugs (somatostatin receptor ligand pasireotide or the dopamine agonist cabergoline), or even drugs that antagonize the glucocorticoid receptor (mifepristone). Given the morbidities associated with hypercortisolism, and the fact that medical treatment can be delivered on a long-term basis, it is important to obtain eucortisolism and to monitor the drug effectively. The efficacy of these drugs will not be detailed in this review, nor their roles in the therapeutic algorithm of Cushing’s disease. This review will rather focus specifically on adverse events associated with these drugs (ketoconazole, levoketoconazole, metyrapone, osilodrostat, pasireotide, cabergoline and mifepristone), and the way in which to monitor and treat them, based on retrospective studies and the most recently published prospective studies.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-527039" status="VALID">
          <idno type="RNSR">200816536U</idno>
          <orgName>Marseille medical genetics - Centre de génétique médicale de Marseille</orgName>
          <orgName type="acronym">MMG</orgName>
          <date type="start">2018-01-01</date>
          <desc>
            <address>
              <addrLine>Faculté de Médecine - Timone27, boulevard Jean Moulin13385 Marseille cedex 5</addrLine>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation name="UMR_S1251" active="#struct-198056" type="direct"/>
            <relation name="UMR_S1251" active="#struct-303623" type="direct"/>
          </listRelation>
        </org>
        <org type="regrouplaboratory" xml:id="struct-1006998" status="VALID">
          <orgName>Institut Marseille Maladies Rares</orgName>
          <orgName type="acronym">MarMaRa</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>Institut MarMaRaMMG-Faculté de Médecine27 bd Jean Moulin, 13385 Marseille Cedex 5</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.univ-amu.fr/marmara</ref>
          </desc>
          <listRelation>
            <relation active="#struct-198056" type="direct"/>
          </listRelation>
        </org>
        <org type="regrouplaboratory" xml:id="struct-533507" status="VALID">
          <orgName>Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM]</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">http://fr.ap-hm.fr/service/endocrinologie-diabete-maladies-metaboliques-hopital-conception</ref>
          </desc>
          <listRelation>
            <relation active="#struct-198056" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-198056" status="VALID">
          <idno type="IdRef">15863621X</idno>
          <idno type="ISNI">0000 0001 2176 4817</idno>
          <idno type="ROR">https://ror.org/035xkbk20</idno>
          <orgName>Aix Marseille Université</orgName>
          <orgName type="acronym">AMU</orgName>
          <date type="start">2012-01-01</date>
          <desc>
            <address>
              <addrLine>Aix-Marseille UniversitéJardins du Pharo58 Boulevard Charles Livon13284 Marseille cedex 7</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-amu.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>